Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unecritinib in advanced malignant tumor
NCT04412564Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of unecritinib in advanced malignant solid tumor, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
unecritinib
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT04412564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412564.